quantity, as well as daytime functioning, while avoiding adverse events
and next-morning residual effects. Current recommended treatment of
insomnia includes sleep hygiene recommendations, cognitive behavioral
therapy and pharmacotherapy.
Key literature
-- Hudgens S, et al. Patient. 2020;14(2): 249-268.
-- Dauvilliers, Y., et al. Ann Neurol. 2020;87(3): 347-356.
-- Muehlan, C., et al. J Clin Psychopharmacol. 2020;40(2): 157-166.
-- Muehlan, C., et al. J Psychopharmacol. 2020;34(3): 326-335.
-- Wardle-Pinkston S, et al. Sleep Med Rev.2019;48:101205.
-- Altinas HK, et al. Int J Nurs Pract. 2019;25(5):e12766.
-- Boof, M. L., et al. Eur J Clin Pharmacol. 2019;75(2): 195-205.
-- Muehlan, C., et al. Curr Drug Metab. 2019;20(4): 254-265.
-- Muehlan, C., et al. Eur Neuropsychopharmacol. 2019;29(7): 847-857.
-- Muehlan, C., et al. Clin Pharmacol Ther. 2018;104(5): 1022-1029.
-- Wang C, et al. Front Mol Neurosci. 2018;11:220.
-- Olfson M, et al. J Clin Psychiatry. 2018;79(5):17m12020.
-- Purves D, et al. Chapter 28. In: Neuroscience. 6th ed. Sunderland, MA;
Oxford University Press; 2018.
-- Treiber A, et al. J Pharmacol Exp Ther. 2017;362(3):489-503.
-- Kryger M, et al, eds. Principles and Practice of Sleep Medicine. 6th ed.
Philadelphia, PA: Elsevier; 2017.
-- Levenson JC, et al. Chest. 2015;147(4):1179-1192.
-- The Diagnostic and Statistical Manual of Mental Disorders (5th ed.;
DSM--5; American Psychiatric Association, 2013).
-- Buysse DJ, et al. Drug Discov Today Dis Models. 2011;8(4):129-137.
-- Walsh JK, et al. Sleep. 2011;34(8):997-1101.
-- Brisbare-Roch, C., et al. Nat Med. 2007;13(2): 150-5.
-- Nofzinger EA, et al. Am J Psychiatry. 2004;161(11):2126-2128.
-- Ohayon, Sleep Medicine Reviews 6(2002)
About Idorsia
Idorsia Ltd is reaching out for more -- We have more ideas, we see more
opportunities and we want to help more patients. In order to achieve
this, we will develop Idorsia into a leading biopharmaceutical company,
with a strong scientific core.
Headquartered near Basel, Switzerland -- a European biotech-hub --
Idorsia is specialized in the discovery, development and
commercialization of small molecules to transform the horizon of
therapeutic options. Idorsia has a broad portfolio of innovative drugs
in the pipeline, an experienced team of professionals covering all
disciplines from bench to bedside, state-of-the-art facilities, and a
strong balance sheet -- the ideal constellation to translate R&D efforts
into business success.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in
June 2017 and has over 900 highly qualified specialists dedicated to
realizing our ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate
Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com
The above information contains certain "forward-looking statements",
relating to the company's business, which can be identified by the use
of forward-looking terminology such as "estimates", "believes",
"expects", "may", "are expected to", "will", "will continue", "should",
"would be", "seeks", "pending" or "anticipates" or similar expressions,
or by discussions of strategy, plans or intentions. Such statements
include descriptions of the company's investment and research and
development programs and anticipated expenditures in connection
therewith, descriptions of new products expected to be introduced by the
company and anticipated customer demand for such products and products
in the company's existing portfolio. Such statements reflect the current
views of the company with respect to future events and are subject to
certain risks, uncertainties and assumptions. Many factors could cause
the actual results, performance or achievements of the company to be
materially different from any future results, performances or
achievements that may be expressed or implied by such forward-looking
statements. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual
results may vary materially from those described herein as anticipated,
believed, estimated or expected.
Anhang
-- Medienmitteilung PDF
https://ml-eu.globenewswire.com/Resource/Download/5a6d0a72-d3d6-4d3e-af9c-2fadc7b16ce5
(END) Dow Jones Newswires
March 10, 2021 01:00 ET (06:00 GMT)